|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Subcutaneous Golimumab Induces Clinical Response and Remission in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Toshifumi Hibi Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 6 |
| 2 | Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial显示文摘 | Stephen B Hanauer Brian G Feagan Gary R Lichtenstein Lloyd F Mayer S Schreiber Jean Frederic Colombel Daniel Rachmilewitz Douglas C Wolf Allan Olson Weihang Bao Paul Rutgeerts | 2002 | The Lancet2002，，9317： | 6 |
| 3 | Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis显示文摘 | Remo Panaccione Subrata Ghosh Stephen Middleton Juan R. Márquez Boyd B. Scott Laurence Flint Hubert JF. van Hoogstraten Annie C. Chen Hanzhe Zheng Silvio Danese Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 5 |
| 4 | Subcutaneous Golimumab Maintains Clinical Response in Patients with Moderate-To-Severe Ulcerative Colitis显示文摘 | William J. Sandborn Brian G. Feagan Colleen Marano Hongyan Zhang Richard Strauss Jewel Johanns Omoniyi J. Adedokun Cynthia Guzzo Jean-Frederic Colombel Walter Reinisch Peter R. Gibson Judith Collins Gunnar J?rnerot Paul Rutgeerts | 2013 | Gastroenterology2013，，： | 5 |
| 5 | Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn’s Disease: Data From the EXTEND Trial显示文摘 | Paul Rutgeerts Gert Van Assche William J. Sandborn Douglas C. Wolf Karel Geboes Jean–Frédéric Colombel Walter Reinisch Ashish Kumar Andreas Lazar Anne Camez Kathleen G. Lomax Paul F. Pollack Geert D’Haens | 2012 | Gastroenterology2012，，5： | 4 |
| 6 | Controlled trial of metronidazole treatment for prevention of crohn’s recurrence after ileal resection显示文摘 | Paul Rutgeerts Martin Hiele Karel Geboes Marc Peeters Freddy Penninckx Raymond Aerts Raymond Kerremans | 1995 | Gastroenterology1995，，6： | 4 |
| 7 | Human Anti–Tumor Necrosis Factor Monoclonal Antibody (Adalimumab) in Crohn’s Disease: the CLASSIC-I Trial显示文摘 | Stephen B. Hanauer William J. Sandborn Paul Rutgeerts Richard N. Fedorak Milan Lukas Donald MacIntosh Remo Panaccione Douglas Wolf Paul Pollack | 2006 | Gastroenterology2006，，2： | 4 |
| 8 | <ce:link locator='fx1'/> Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM Trial显示文摘 | Jean–Frédéric Colombel William J. Sandborn Paul Rutgeerts Robert Enns Stephen B. Hanauer Remo Panaccione Stefan Schreiber Dan Byczkowski Ju Li Jeffrey D. Kent Paul F. Pollack | 2007 | Gastroenterology2007，，1： | 4 |
| 9 | Pharmacogenetics in inflammatory bowel disease显示文摘遗传药理学是在在药反应的可变性之间的协会的学习并且(或) 在基因的药毒性和多型性。科学的这个领域的目标是使药适应一个病人的特定的基因背景因此使他们更有效、安全。在这篇文章,我们在影响的基因描述变体在煽动性的肠疾病( IBD )的治疗使用的普通的药的功效或毒性, ulcerative ( UC ),和 Crohn 包括 sulfasalazine 和 mesalazine 是疾病( CD ), azathioprine ( AZA )和 6-mercaptopurine ( 6-MP ), methotrexate ( MTX ), glucocorticosteroids ( CS )和 infliximab 。而且, pharmacogenetic 研究的困难一般来说并且更明确地在 IBD 被描述。尽管遗传药理学是已经贡献了一些药的行动的内在的机制的更好的理解的一个有希望的领域,在 IBD 使用,翻译直到现在成每日的实践的唯一的发现是在 thiopurine S-methyltransferase (TPMT ) 基因多型性和 thiopurine 治疗的 hematological 毒性之间的关系。在未来,在很好描绘的耐心的队组织研究是必要的谁一致地被对待并且系统地评估了以便测定药反应更客观地。一个努力应该被作从为 pharmacogenetic 研究在适当知情同意以后在临床的药试用注册的所有病人收集 genomic DNA。 | Marie Pierik Paul Rutgeerts Robert Vlietinck Severine Vermeire | 2006 | World Journal of Gastroenterology2006，12，23： | 3 |
| 10 | Biological Therapies for Inflammatory Bowel Diseases显示文摘 | Paul Rutgeerts Severine Vermeire Gert Van Assche | 2009 | Gastroenterology2009，，4： | 3 |
| 11 | Role of genetics in prediction of disease course and response to therapy显示文摘The clinical course of Crohn's disease and ulcerative colitis is highly variable between patients,and this has therapeutic implications.A number of clinical features have been identified,which predict a mild or more severe outcome.However,several of these are subjective and/or not persistent over time.With the progress in genetics research in inflammatory bowel disease(IBD),genetic markers are increasingly being proposed to improve stratification of patients.Genetics have the major advantage of being stable over time and not prone to subjective interpretation.Nevertheless,none of the genetic variants associated with particular outcomes have shown sufficient sensitivity or specificity to have been implemented in daily management.Along the same line of thinking,pharmacogenetics or the study of association between variability in drug response and genetic variation has also received more attention as part of the endeavor for personalized medicine.The ultimate goal in this area of medicine is to adapt medication to a patient's specific genetic background and therefore improve on efficacy and safety rates.Although pharmacogenetic studies have been performed for all classes of drugs applied in IBD,few have generated consistent findings or have been replicated.The only genetic test approved for clinical practice is thiopurine S-methyltransferase testing prior to starting treatment with thiopurine analogues.The other reported associations have suffered from lack of confirmation or still need replication efforts.Nevertheless,the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed. | Severine Vermeire Gert Van Assche Paul Rutgeerts | 2010 | World Journal of Gastroenterology2010，16，21： | 3 |
| 12 | Review article: the role of anti‐TNF in the management of ulcerative colitis – past, present and future显示文摘 | S. Danese J.‐F. Colombel L. Peyrin‐Biroulet P. Rutgeerts W. Reinisch | 2013 | Aliment Pharmacol Ther2013，，9： | 3 |
| 13 | Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis显示文摘 | Jean Frédéric Colombel Paul Rutgeerts Walter Reinisch Dirk Esser Yanxin Wang Yinghua Lang Colleen W. Marano Richard Strauss Bj?rn J. Oddens Brian G. Feagan Stephen B. Hanauer Gary R. Lichtenstein Daniel Present Bruce E. Sands William J. Sandborn | 2011 | Gastroenterology2011，，4： | 3 |
| 14 | <ce:link locator='fx1'/> A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis显示文摘 | Geert D’Haens William J. Sandborn Brian G. Feagan Karel Geboes Stephen B. Hanauer E. Jan Irvine Marc Lémann Philippe Marteau Paul Rutgeerts Jurgen Sch?lmerich Lloyd R. Sutherland | 2007 | Gastroenterology2007，，2： | 2 |
| 15 | 那他珠单抗治疗克隆病后导致进行性多灶性脑白质病 | Van Assche G. Van Ranst M. Sciot R. P. Rutgeerts 郭俊 | 2005 | 世界核心医学期刊文摘(神经病学分册)2005，0，12： | 2 |
| 16 | Lymphocytes and Langerhans cells in the human oesophageal epithelium显示文摘 | K. Geboes C. Wolf-Peeters P. Rutgeerts J. Janssens G. Vantrappen V. Desmet | 1983 | Virchows Archiv A Pathological Anatomy and Histopathology1983，，1： | 2 |
| 17 | Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease显示文摘 | Peter Suenaert Veerle Bulteel Liesbeth Lemmens Maja Noman Benny Geypens Gert Van Assche Karel Geboes Jan L Ceuppens Paul Rutgeerts | 2002 | The American Journal of Gastroenterology2002，，8： | 2 |
| 18 | Infliximab, Azathioprine, or Infliximab + Azathioprine for Treatment of Moderate to Severe Ulcerative Colitis: The UC Success Trial显示文摘 | Remo Panccione Subrata Ghosh Stephen Middleton Juan R. Marquez Igor Khalif Laurence Flint Hubert van Hoogstraten Hanzhe Zheng Silvio Danese Paul J. Rutgeerts | 2011 | Gastroenterology2011，，5： | 2 |
| 19 | Future directions in inflammatory bowel disease management显示文摘 | Geert R. D’Haens R. Balfour Sartor Mark S. Silverberg Joel Petersson Paul Rutgeerts | 2014 | Journal of Crohn’s and Colitis2014，，： | 2 |
| 20 | Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed显示文摘 | Bruce E. Sands Brian G. Feagan Paul Rutgeerts Jean-Frédéric Colombel William J. Sandborn Richmond Sy Geert D’Haens Shomron Ben-Horin Jing Xu Maria Rosario Irving Fox Asit Parikh Catherine Milch Stephen Hanauer | 2014 | Gastroenterology2014，，： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员